22 novembre 2017 | Khondrion Presents Phase II KHENERGY Trial Data
Padova News,
– Data supporting Phase III development of KH176 in mitochondrial disease Khondrion, a leading clinical-stage pharmaceutical…
– Data supporting Phase III development of KH176 in mitochondrial disease Khondrion, a leading clinical-stage pharmaceutical…
Nijmegen, Niederlande - Daten befürworten die Phase III der Entwicklung von KH176 für mitochondriale Erkrankungen Khondrion…
/PRNewswire/ -- Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for…